At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MTVA MetaVia Inc
Post-Mkt 03-13 18:00:48 EDT
1.61
+0.00
0.00%
盘后1.63
+0.02+1.24%
17:58 EDT
High1.67
Low1.57
Vol48.80K
Open1.63
D1 Closing1.61
Amplitude5.90%
Mkt Cap5.17M
Tradable Cap3.68M
Total Shares3.21M
T/O78.82K
T/O Rate2.13%
Tradable Shares2.29M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
MetaVia expands vanoglipel patent portfolio protection into 2035
BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.